Clinical characteristics and treatment patterns of older and younger patients with inflammatory bowel disease

Table 1 Demographic characteristics of adult nongeriatric and geriatric patients with inflammatory bowel disease

	Total, n = 1245			UC, n = 618			CD, n = 627
	Older-onset, n = 56	Younger-onset, n = 1189	P value/OR (95%CI)	Older-onset UC, n = 39	Younger-onset UC, n = 579	P value/OR (95%CI)	Older-onset CD, n = 17	Younger-onset CD, n = 610	P value/OR (95%CI)
Age at the onset of IBD (median year)	71.5	46	< 0.001	72	49	< 0.001	71	43	< 0.001
Total disease duration (median year)	6	11	< 0.001	6	12	< 0.001	6	11	< 0.001
Prodromal period (median month)	3	4	0.687	2	1	0.247	7	11	0.976
Female/male	15 (27)/41 (73)	464 (42)/725 (58)	0.066	8 (21)/31 (79)	215 (37)/364 (63)	0.036	7 (41)/10 (59)	249 (41)/361 (59)	0.036
Smokers (current/ex/non)	6 (10)/29 (52)/21 (38)	277 (23)/368 (31)/544 (46)	0.003	4 (10)/20 (51)/15 (39)	75 (13)/206 (36)/298 (51)	0.143	2 (12)/9 (53)/6 (35)	202 (33)/162 (27)/246 (40)	0.04
Family history of IBD	2 (4)	155 (13)	0.03/0.25 (0.06-1.01)	1 (2.6)	80 (13.8)	0.044	1 (5.9)	75 (12.3)	0.708
Surgery during follow-up	20 (35.7)	464 (39)	0.619	8 (20.5)	89 (15.4)	0.393	12 (70.6)	375 (61.5)	0.446
Hospitalized at the time of diagnosis	13 (23.2)	422 (35.5)	0.060	5 (12.8)	142 (24.5)	0.097	8 (47.1)	280 (45.9)	0.925
Hospitalized for conditions related to IBD	23 (41.1)	571 (48)	0.309	14 (35.9)	184 (31.8)	0.594	9 (52.9)	387 (63.4)	0.376
BMI (kg/m2)	25	24	0.109	24.5	25	0.663	29	23	0.016
UC/CD	39 (69.6)/17 (30.4)	579 (48.7)/610 (51.3)	0.002/2.42 (1.35-4.32)	-	-	-	-	-	-
UC (disease extent)
Proctitis	6 (15.4)	53 (9.2)	0.414	6 (15.4)	53 (9.2)	0.414	-	-	-
Left side	17 (43.6)	288 (49.7)		17 (43.6)	288 (49.7)		-	-	-
Extensive	16 (41)	238 (41.1)		16 (41)	238 (41.1)		-	-	-
CD (disease location)
Ileal (L1)	9 (52.9)	260 (42.9)	0.005	-	-	-	9 (52.9)	260 (42.9)	0.005/1.49 (1.10-2.10)
Colonic (L2)	1 (5.9)	81 (13.1)		-	-	-	1 (5.9)	81 (13.1)
Ileo-colonic (L3)	5 (29.4)	267 (43.4)		-	-	-	5 (29.4)	267 (43.4)
Upper GI disease (L4)	2 (11.8)	2 (0.6)		-	-	-	2 (11.8)	2 (0.6)
CD (disease behavior)						-
Inflammatory disease (B1)	12 (70.6)	457 (74.8)	0.065	-	-	-	12 (70.6)	457 (74.8)	0.065
Stenosing (B2)	4 (23.5)	49 (8.5)		-	-	-	4 (23.5)	49 (8.5)
Penetrating (B3)	1 (5.9)	104 (16.7)		-	-	-	1 (5.9)	104 (16.7)
CD P (perianal disease)	3 (17.6)	202 (32.7)	0.180	-	-	-	3 (17.6)	202 (32.7)	0.180
EIMs	18 (32.1)	606 (51)	0.006/0.46 (0.26-0.81)	12 (30.8)	272 (47)	0.04/0.50 (0.25-1.02)	6 (35.3)	334 (54.8)	0.112
Erythema nodosum	0	27	0.630	0	11	1.0	0	16	1.0
Pyoderma gangrenous	0	9	1.0	0	3	1.0	0	6	1.0
Peripheral arthralgia	10	380	0.026	6	168	0.067	4	212	0.337
Peripheral arthritis	0	107	0.012	0	36	0.157	0	71	0.241
Back pain	9	201	0.871	5	82	0.816	4	119	0.756
Ankylosing spondylitis	1	68	0.363	1	27	1.0	0	41	0.619
Sacroiliitis	0	31	0.396	0	10	1.0	0	21	1.0
Aphthous ulcer	4	238	0.017	2	122 g	0.016/0.20 (0.05-0.86)	2	116	0.752
Thromboembolism	0	31	0.396	0	15	0.615	0	16	1.0
Osteoporosis	2	19	0.243	2	7	0.105	0	12	1.0
PSC	2	19	0.243	2	7	0.105	0	12	1.0
Uveitis	0	16	1.0	0	6	1.0	0	10	1.0
Episcleritis	0	5		0	2	1.0	0	3	1.0
Medications (conventional)
Thiopurine	9 (16.1)	391 (32.9)	0.008/0.39 (0.19-0.81)	7 (17.9)	100 (17.3)	0.914	2 (11.8)	291 (47.7)	0.003/0.08 (0.01-0.41)
Methotrexate	0	51 (4.3)	0.165	0	5 (0.9)	1.0	0	46 (7.5)	0.628
Sulfasalazine	0	53 (4.5)	0.167	0	10 (1.7)	1.0	0	43 (7)	0.622
Mesalazine	10 (17.9)	407 (34.2)	0.011	8 (20.5)	122 (21.1)	0.934	2 (11.8)	285 (46.7)	0.004
Budesonide	11 (19.6)	324 (27.2)	0.210	9 (23.1)	114 (19.7)	1.0	2 (11.8)	210 (34.4)	0.243
Steroids	0	75 (6.3)	0.044	0	2 (0.3)	0.608	0	73 (12)	0.051
Cyclosporin	1 (1.8)	1 (0.1)	0.088	0	0	0.914	0	0	-
Biological therapy	15 (26.8)	586 (49.3)	0.001/0.38 (0.21-0.69)	11 (28.2)	157 (27.1)	0.882	4 (23.5)	429 (70.3)	< 0.001/0.13 (0.04-0.40)
Infliximab	9 (16.1)	365 (30.7)	0.02/0.43 (0.20-0.90)	6 (15.4)	99 (17.1)	0.783	3 (17.6)	266 (43.6)	0.033/0.28 (0.08-0.97)
Adalimumab	6 (10.7)	384 (32.8)	< 0.001/0.25 (0.11-0.59)	4 (10.3)	93 (16.1)	0.335	2 (11.8)	291 (47.7)	0.003/0.15 (0.03-0.64)
Vedolizumab	6 (10.7)	111 (9.3)	0.730	6 (15.4)	36 (6.2)	0.041/2.74 (1.08-6.97)	0	75 (12.3)	0.246
Ustekinumab	1 (1.8)	81 (6.8)	0.173	1 (2.6)	13 (2.2)	0.603	0	69 (11.1)	0.240
Sertolizumab	0	31 (2.6)	0.396	0	3 (0.5)	1.0	0	28 (4.6)	1.0
Steroid dependence	21 (37.5)	532 (44.7)	0.286	1 (2.6)	6 (1)	0.649	5 (29.4)	306 (50.2)	0.091
Steroid resistance	4 (7.1)	30 (2.5)	0.062	4 (10.3)	16 (2.8)	0.032	0	14 (2.3)	1.0
IM resistance	8 (14.3)	409 (34.4)	0.002/0.32 (0.15-0.68)	4 (10.3)	99 (17.1)	0.267	4 (23.5)	310 (50.8)	0.026/0.30 (0.10-0.90)
Thiopurine side effects	7 (12.5)	141 (11.9)	0.885	4 (10.3)	43 (7.4)	0.527	3 (17.6)	98 (16.1)	0.745
Methotrexate side effects	2 (3.6)	44 (3.7)	1.0	0	2 (0.3)	1.0	0	42 (6.9)	0.338
Biologic resistance/intolerance	0	15 (3)	1.0	0	6 (1)	1.0	0	9 (1.5)	0.377
Baseline Hb concentration (mg/L)	12.6 (2.3)	13 (2.8)	0.332	13 (2.1)	12.9 (2.9)	0.571	12.4 (2.3)	13 (2.8)	0.445
Baseline albumin concentration (g/L)	41 (8.75)	42 (9)	0.574	41 (11)	43 (8)	0.093	42 (10)	41 (-)	0.701
Baseline CRP level (mg/L)	11.4 (28.7)	10.2 (26.9)	0.722	4.8 (30.6)	9.1 (24.3)	0.491	17.3 (23)	11.7 (31)	0.724
Baseline CDAI (CD)	302 (277)	297 (179)	0.728			-	302 (277)	297 (178)	0.377
Baseline total Mayo score	9 (3)	9 (4)	0.847	9 (3)	9 (4)	0.800	-	9.3 2.4	-
Baseline partial Mayo score	7 (2)	7 (2)	0.710	7 (2)	7(2)	0.730	-	6.7 1.8	-

Data are presented as mean ± SD, median (interquartile range), or n (%), unless otherwise stated. IBD: Inflammatory bowel disease; UC: Ulcerative colitis; CD: Crohn’s disease; BMI: Body mass index; GI: Gastrointestinal; EIMs: Extraintestinal manifestations; PSC: Primary sclerosing cholangitis; IM: Immunomodulator; Hb: Hemoglobin; CRP: C-reactive protein; CDAI: Crohn’s Disease Activity Index.